CBDV
Aliases: Gwp42006, Cannabidivarol
Summary
Clinical studies using doses up to 800 mg twice daily for 8 weeks have shown good safety with mostly mild gastrointestinal upset and somnolence. Like CBD, CBDV is a moderate inhibitor of several CYP450 enzymes; use caution with narrow-therapeutic-index drugs. Early evidence suggests anticonvulsant, anti-inflammatory and possible nootropic or attention-enhancing properties.
Dose Information
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Onset | Peak | Offset |
|---|---|---|---|
| Oral | 0.5-2 hrs | 2-4 hrs | 2-3 hrs |
| Smoked | 0-5 min | 15-60 min | 1-2 hrs |
Tolerance
Build-up
develops over weeks of regular use via CB1 receptor downregulation
Reset
2–4 weeks for most users; heavy users may need longer
Tolerance Decay
Full tolerance
0h
Half tolerance
0d
Baseline
~0d
No clear evidence of clinically meaningful tolerance with daily CBDV over weeks to months in limited trials/anecdotes; if present, likely mild and reversible. Cross‑tolerance with CBD is plausible due to overlapping mechanisms, but magnitude is uncertain.
Cross-Tolerances
CBD
50%
Effects
Positive
- Mild anxiolysis
- Decreased seizure frequency
- Reduced inflammation or pain
Positive
- Subtle mood elevation
- Enhanced mental clarity or focus
- Very low or absent intoxication
Combinations
CBDV's nerd page
Pharmacology, chemical data, effect profiles, and more
→